ICP 189
Alternative Names: ICP-189Latest Information Update: 01 Apr 2024
At a glance
- Originator InnoCare Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non receptor type 11 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 29 Mar 2024 InnoCare Pharma in collaboration with ArriVent Biopharma initiates a phase Ib trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (PO)
- 13 Jul 2023 InnoCare Pharma and ArriVent Biopharma enter into clinical development collaboration for ICP 189 for Non-small cell lung cancer
- 13 Jul 2023 InnoCare Pharma in collaboration with ArriVent Biopharma plans a clinical trial for Non-small cell lung cancer (Combination therapy, Late-stage disease)